Cell line · CVCL_0428

MIA PaCa-2

Cancer cell line, Homo sapiens. Pancreatic undifferentiated carcinoma. 295 papers.

4 sourcescell-lines-2026-11-14-0.1.0

Cite this record

ConductScience Library. MIA PaCa-2. Cell lines, record CVCL_0428. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0428

On this page

Cell line

As Cellosaurus gives it.

Name: MIA PaCa-2
Accession: CVCL_0428
RRID: RRID:CVCL_0428
Synonyms: MIA-PaCa-2, MIA-PACA-2, MIA-Pa-Ca-2, MIA Paca2, MIA PaCa2, MiaPaCa-2, MIAPACA-2, MiaPaca.2, MiaPaCa2, Miapaca2, MIAPaCa2, MIAPACA2, Mia PACA 2, MIAPaCa-2, PaCa2, MiaPaCa, MIAMI Pancreatic Carcinoma-2
Species: Homo sapiens (Human)
Sex: Male
Age at sampling: 65Y
Category: Cancer cell line
Diseases: Pancreatic undifferentiated carcinoma (NCIt C5722)
Derived from: Pancreas (in situ)
Entry created: 2012-04-04
Entry updated: 2026-06-25

Source Cellosaurus

Problems1

Problem	Cellosaurus's note
Caution	Additional TP53 mutation in c.818G>A indicated incorrectly in PubMed=1630814.

Source Cellosaurus

Papers295

1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.

Paper	Journal	Year	How we know	Source
Pharmacokinetic Tuning Redirects β‐Lapachone From NQO1 Bioactivation to Vimentin‐Targeted Oxidation in Cancer	Adv Sci (Weinh)	2026	Its Methods give the RRID and name the line	PubMed
o-carborane encapsulated into polymeric micelles for proton boron capture therapy.	Cancer Nanotechnol	2026	Its Methods give the RRID and name the line	PubMed
Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy.	Cancers (Basel)	2026	Its Methods give the RRID and name the line	PubMed
Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Cancer.	Chem Biodivers	2026	Its Methods give the RRID and name the line	PubMed
Therapeutic Efficacy and Safety of Intraperitoneally Administered 211At-Labeled Gold Nanoparticles for Peritoneally Disseminated Malignancies.	Pharmaceutics	2026	Its Methods give the RRID and name the line	PubMed
Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells.	Mol Oncol	2026	Its Methods give the RRID and name the line	PubMed
Type I interferons modulate autophagy to shape gemcitabine response in pancreatic cancer cells.	FEBS Open Bio	2026	Its Methods give the RRID and name the line	PubMed
Dual Targeting of FGFR4 and PI3K-mTOR Suppresses Tumor-Associated Phenotypes in Pancreatic Ductal Adenocarcinoma.	Int J Mol Sci	2026	Its Methods give the RRID and name the line	PubMed
HRAS promotes mutant NRAS-driven transformation with codon and allele specificity.	Sci Signal	2026	Its Methods give the RRID and name the line	PubMed
Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC.	Mol Cancer Ther	2026	Its Methods give the RRID and name the line	PubMed

1 to 10 of 295

See all 295 papers

Relatives10

Relation	Cell line	Accession	Problem	Source
Derived from it	GEM-MIA PaCa-2	CVCL_HA89		Cell lines
Derived from it	HyCyte MIA PaCa-2 KO-hSNAP23	CVCL_F1RV		Cell lines
Derived from it	HyCyte MIA PaCa-2 stable cell line for hABHD17C overexpression	CVCL_F4TY		Cell lines
Derived from it	MIA PaCa-2 GR2000	CVCL_WI23		Cell lines
Derived from it	MIA PaCa-2 GR300	CVCL_WI24		Cell lines
Derived from it	MIA PaCa-2 GR800	CVCL_WI25		Cell lines
Derived from it	MIA PaCa-2/CMV-Luc	CVCL_JG54		Cell lines
Derived from it	MiaPaCa(BCRP)	CVCL_C7SQ		Cell lines
Derived from it	MiaPaCa-2 F-RFP	CVCL_E9C2		Cell lines
Derived from it	PH61-N	CVCL_D282	Has a recorded problem	Cell lines

Cell banks16

Cell bank	Catalog number	Source
ATCC	CRL-1420	ATCC
ATCC	CRM-CRL-1420	ATCC
AddexBio	C0018002/59	Cellosaurus
BCRC	60139	BCRC
BCRJ	0174	BCRJ
CCTCC	GDC0255	Cellosaurus
CLS	300438	CLS
DSMZ	ACC-733	DSMZ
ECACC	85062806	ECACC
Hysigen	TCH-C259	Hysigen

1 to 10 of 16

See all 16 cell banks

Data dates

The date of each source this release read.

Cellosaurus: 2026-10-22; Cellosaurus
PubMed Central's articles: 2026-11-12; PubMed Central's articles
Our copy of PubMed: 2026-11-06; Our copy of PubMed

Sources 4

CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
PubMedNLM's terms

Each source's terms

CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this cell line from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_0428

GET https://conductscience.org/api/cell-lines/v1/CVCL_0428/papers?page=2

API reference For AI assistants